Block Grant Requirements and Tuberculosis in Substance Abusing Populations
|
|
- Hubert Conley
- 6 years ago
- Views:
Transcription
1 Block Grant Requirements and Tuberculosis in Substance Abusing Populations Christine Pickens RNBC,M.Ed. Operation Par, Inc. This product is supported by Florida Department of Children and Families Substance Abuse and Mental Health Program Office funding.
2 OVERVIEW Brief review of Block Grant Introduction to Linkage Tuberculosis (TB) Risk and Prevalence among Drug Abusers Treatment Adherence Targeted Testing Treatment Considerations Q&A
3 WHAT IS THE BLOCK GRANT?
4 TB and Substance Abuse a block grant is a large sum of money granted by the national government to a regional government with only general provisions as to the way it is to be spent. Substance Abuse Prevention and Treatment Grant
5 BLOCK GRANT SAPT WOMEN & DEP. CHILDREN COMMUNICABLE DISEASES CAPACITY MANAGM T INTERIM SERVICES SERVICE COORDINATION OTHER REQUIREMENTS HIV TB PEER REVIEW CONTINUING EDUCATION
6 WHAT IS THE BETWEEN SUBSTANCE ABUSE AND TB?
7 PREVALENCE 19% of reported TB cases also report abusing alcohol or using illicit & injectable drugs(idu) 1.8 times more likely to have a more contagious or virulent form of TB Female substance abusers were 2.5 times more likely to experience TB treatment failure than other females
8 PREVALENCE DEFINITIONS: LATENT TUBERCULOSIS INFECTION: TB bacteria can live in your body without making you sick. Immune system strong and able to stop bacteria from growing. Are not infectious and cannot spread the bacteria Can progress to Active TB ACTIVE TUBERCULOSIS DISEASE: Immune system can t stop bacteria from growing Infection can progress to disease People are sick able to spread
9 PREVALENCE ADDICTION Addiction is defined as a chronic, relapsing brain disease that is characterized by compulsive drug seeking and use, despite harmful consequences.
10 Physiological factors Immunosuppression PREVALENCE IDU or alcohol abuse weakens immune system and cannot battle exposure Stay contagious longer Longer to achieve a negative culture Overall increase risk of mortality HIV infected IDUs are at greater risk Each disease speeds up the progress of the other
11 PREVALENCE Epidemiological Risk Factors: Tobacco use between 75 95% of persons in SA treatment smoke. Homelessness 35% of all sheltered adults had chronic SA issues Incarceration 75% of inmates meet DSM V criteria for substance use disorders
12 BARRIERS and CHALLENGES Unstable lifestyle Lack of primary care or health insurance Perceived stigma about SA and TB Lack of knowledge about TB and inability to recognize symptoms Wait to present to treatment until after symptom onset which can increase transmission rate as well as severity of disease
13 BARRIERS AND CHALLENGES Two hallmarks of TB control are: 1. Effective identification of TB cases 2. Effective treatment Where Are you
14 BARRIERS and CHALLENGES Drugs may suppress cough reflex and recognition and patient delay (morphine and opiates) Reluctance and low motivation to seek treatment Fail to return for reading of tuberculin skin test (tst) Fear of narcotic withdrawal if hospitalized Confusion of prevention (bleaching needles or condom use does not affect transmission. TB can be prevented using similar prevention methods used for HIV or hepatitis transmission.
15 TB MEDICATIONS AND SA TB treatment meds may increase drug induced hepatitis esp. if co infected with HIV and Viral Hepatitis Rifampin causes a decreased half life of many illicit drugs hence alters the high requiring more Directly affects methadone requiring increase dose amounts. This is the leading medication of choice for opiate addicted drug users.
16 STRATEGIES Collaboration and coordination of services across agencies and treatment providers Training for staff focused on Substance Abuse and TB for personnel across agencies Targeted testing for easier identification Continued efforts and education with this high risk population
17 QUESTIONS????
18 Part I: Public Health Laws for TB Control in Florida Karen Farrell, RN, BSN, RM, Executive Community Nursing Services Director Bureau of Communicable Diseases, TB Control Section, Florida Department of Health This product is supported by Florida Department of Children and Families Substance Abuse and Mental Health Program Office funding.
19 Communicable Disease Prevention & Control
20 Tuberculosis Control
21 Tuberculosis Control Program Strategies Treat to Cure Protect Close Contacts Prevent TB Disease Laboratories Health Care Providers FDOH Assure TB Outcome Federally Qualified Health Centers Ensure Infection Prevention Monitor & Evaluate Hospitals Academia Social Service Agencies
22 Community TB Program (s , F.S.) Each community TB program will have: Community & professional education Community & individual screening Surveillance and contact investigation Reporting of all known cases Development of individualized treatment plan Provision of counseling, periodic retesting, and referral to appropriate agencies
23 Confidentiality (s , F.S.) Exempt from s (1), F.S. All records & information related to: known or suspected cases exposure to TB Specifics for release of information are provided
24 Surveillance Requirements 1. Reporting Required (s , F.S.) a) Who: Person who makes a diagnosis or treats a person with TB Laboratory where specimen reveals tubercule baccilli b) When: Next Business Day (64D-3.029, F.A.C.) Physicians next business day Labs next business day c) Where: FDOH CHD d) How: DOH Disease Report Form (DH Form 2136, 3/06) Form supplied by provider
25 Surveillance Requirements (continued) 2. Contact Investigation (s , F.S.) a) Who: FDOH may counsel and interview any person with active TB, suspected of having active TB or suspected of having been exposed to active TB b) Information gathered is confidential and exempt from s (1), F.S.
26 Physical Exam & Treatment (s , F.S.) WHO: Diagnosis has active TB or reasonably suspected of having TB Been exposed to active TB WHEN: Voluntary (consent) or court-ordered WHERE: Private physician or CHD facility (outpatient)
27 Treatment (continued) Diagnosed with active TB Treatment Plan (s , F.S) a) Provider licensed under Chapter 458, 459, or 464, F.S. b) Implement using a case management approach c) Address non-compliance
28 Treatment (continued) Isolation in Home/Hospitalization (s , F.S.) Voluntary Court-Ordered when: Active TB; Poses a public health threat Exhausted reasonable means to achieve compliance Note: court order expires in 180 days or when patient is no longer a public health threat If longer than 180 days, hearing must be held within 14 days of expiration Contracted Providers for Hospitalization
29 Enforcement of 392 & 64 D The State Health Officer or his or her designee can execute a Certificate of Involuntary Hold The department can petition the courts for: Petitions for Examination and Treatment Petitions for Directly Observed Therapy Residential Isolation Petitions for Hospitalization Petitions for Emergency Hold
30 Non-adherence Failure to adhere to the prescribed TX plan: May be due to a willful disregard by a fully competent individual May be related to addictions or chemical dependency Related to mental capacity Action required; may involve, Court ordered community supervision Hospitalization or residential treatment program, vs. incarceration
31 Addressing Non-adherence (continued) But I Don t Want A Test! I Feel Fine Educate the client & document the education , Florida Statutes requires physical examination and treatment, if appropriate If the client doesn t cooperate, an examination and treatment warrant may be issued!
32 Addressing Non-adherence If they still refuse (continued) The DOH will initiate court proceedings for a Petition for Examination and Treatment The court will issue a warrant And if they still refuse?
33 Certificate of Involuntary Hold for Tuberculosis F.S & Rule: 64D Execution of Certificate for Involuntary Hold for Tuberculosis Appropriate when: Active or presumptively active TB Threat to the public Unlikely to appear at a scheduled hearing The treating physician has determined a need for involuntary hospitalization or commitment
34 Petitions for Court-Ordered DOT (1) (2) - Appropriate for: Any client with DOT or DOPT prescribed as part of their treatment plan Typically used: Repeat No call/no show for DOT or clinic visits, despite counseling Step to avoid involuntary commitment High-risk contacts
35 Petitions for Hospitalization or Placement Appropriate for: Active or presumptive TB Threat to public Non-adherent despite counseling All other reasonable means of achieving compliance exhausted Hearing has been held
36 Petitions for Emergency Hold Appropriate if: Active or presumptive TB Poses a threat to public Not likely to show for a scheduled hearing Words or actions provide evidence of being likely to leave jurisdiction prior to hearing date Likely to continue exposing the public until hearing
37 Take Note!
38 TB MATH Active TB + 1. Not taking all meds 2. Missing clinic appointments 3. Missing DOT Appointments, or 4. Failing to adhere to MD orders: -drinking alcohol - illegal drug use -recreational prescription drug use = Non-adherence
39 Get the Ball Rolling Document all education, counseling and interventions in detail, from day ONE Address non-adherence with local DOH leadership and legal Notify the TBCS via and phone call Conference call will be scheduled, case will be reviewed and appropriate guidance will be given, including action, if justified
40 Contact: Tuberculosis Control Section (850)
41 PART II: Tuberculosis Overview: Karen Farrell, RN, BSN, RM Executive Community Nursing Services Director Bureau of Communicable Diseases, TB Control Section, Florida Department of Health
42 The Lord shall smite thee with a consumption and with a fever, and with an inflammation... and they shall pursue thee until thou perish. Deuteronomy 28:22
43 Expected and Observed TB Cases United States,
44 Factors Contributing to the Increase in TB Morbidity: Emerging HIV/AIDS epidemic Immigration from countries where TB was common Transmission of TB in congregate settings Development of multidrug-resistant (MDR) TB Decades of funding cuts had impaired effectiveness of TB control programs
45 30,000 25,000 20,000 15,000 10,000 5,000 0 Reported TB Cases United States,
46 Tuberculosis Infected cases GLOBAL 1.7 billion (33% population) USA 10 million (4% population) Case incidence 8-9 million/year ~ 9,400/year Case prevalence million ~14 thousand Deaths 1.3 million/year 1,000-2,000/year MDR Up to 15% (Dominican Republic and Ecuador) < 1%
47 Persons at Higher Risk for Exposure to or Infection with TB Close contacts of person known or suspected to have active TB Foreign-born persons from areas where TB is common Persons who visit TB-prevalent countries Residents and employees of high-risk congregate settings
48 Persons at Higher Risk for Exposure to or Infection with TB (cont.) Health care workers (HCWs) who serve high-risk clients Populations defined locally as having increased incidence of latent M. tuberculosis infection or TB disease, such as medically underserved, low-income persons who abuse drugs or alcohol Children and adolescents exposed to adults at increased risk for infection or disease
49 Everyone knows the air is terribly infected from the mortals who have died exhaling it. Moby Dick Herman Melville
50 Transmission of Tuberculosis
51 Pathogenesis of Tuberculosis
52 Probability TB Will Be Transmitted Susceptibility of the exposed person Infectiousness of person with TB (i.e., number of bacilli TB patient expels into the air) Environmental factors that affect the concentration of M. tb organisms Proximity, frequency, and duration of exposure (e.g., close contacts) Can be transmitted from children, though less likely
53 Sites of Disease Lungs (pulmonary): most common site; usually infectious Miliary: occurs when bacilli spread to all parts of the body; rare, but fatal if untreated Central nervous system: usually occurs as meningitis, but can occur in brain or spine
54 Sites of Disease (cont.) Outside the lungs (extrapulmonary): usually not infectious, unless person has: Concomitant pulmonary disease, Extrapulmonary disease in the oral cavity or larynx, or Extrapulmonary disease with open site, especially with aerosolized fluid.
55 Extra-pulmonary TB ~10% in HIV(-) HIV(+) 33% with extrapulmonary alone 33% with pulmonary alone 33% both pulmonary and extrapulmonary (many with negative CXRs) Any organ has been noted to be involved Pleural dx most common Lymph nodes GU Bone (Need to prolong therapy) Abdominal CNS (Need to prolong therapy)
56 LTBI vs. TB Disease Person with TB Disease Person with LTBI (Infected) (Infectious) Has a small amount of TB bacteria in his/her body that are alive, but inactive Cannot spread TB bacteria to others Does not feel sick, but may become sick if the bacteria become active in his/her body Usually has a TB skin test or TB blood test reaction indicating TB infection Radiograph is typically normal Sputum smears and cultures are negative Should consider treatment for LTBI to prevent TB disease Does not require respiratory isolation Not a TB case Has a large amount of active TB bacteria in his/her body May spread TB bacteria to others May feel sick and may have symptoms such as a cough, fever, and/or weight loss Usually has a TB skin test or TB blood test reaction indicating TB infection Radiograph may be abnormal Sputum smears and cultures may be positive Needs treatment for TB disease May require respiratory isolation A TB case
57 Progression from Infection to Disease is Increased by... HIV infection X-ray evidence of old, untreated TB Substance abuse, injecting drug use Silicosis, diabetes Certain therapies Certain cancers To protect, Underweight promote and improve the health of all by people in 10% Florida through or integrated more state, county, and community efforts.
58 Division Tuberculosis of Disease Control and Health Protection Overview: Disease Progression Progression from infection to disease caused by an inability to contain infection 5-10% of all HIV(-) will progress from infection to disease Up to 8% per year of TST(+), HIV(+) patients will progress from infection to disease The average patient with active TB infects 30 other individuals
59 Drug-Resistant TB Caused by organisms resistant to one or more TB drugs Transmitted same way as drugsusceptible TB, and no more infectious Delay in detecting drug resistance may prolong period of infectiousness because of delay in starting correct treatment
60 Clinical Significance of Resistance If pansensitive > 95% chance of cure If resistant to INH > 90% chance of cure If resistant to rifampin > 70% chance of cure If resistant to INH and RIF ~ 50% chance of cure Before chemotherapy ~ 50% chance of cure
61 Transmission and Pathogenesis of TB Tuberculosis is spread by airborne droplets ( droplet nuclei ) Most persons exposed to a person with tuberculosis do not become infected Close contacts are at high risk of acquiring infection Ten percent of infected persons will develop clinical tuberculosis Persons with tuberculosis infection but no disease are not contagious Cavitary or smear positive patients are more infectious than noncavitary or smear negative patients
62 Diagnosis of Active TB Disease Key: THINK TB
63 Infection Control Think TB, isolate, and start meds Six to eight air exchanges/hour Negative pressure Doors closed All entering room wear N95 mask Keep in isolation until three negative smears, on medications To protect, and promote responding and improve the health of all people in clinically Florida through integrated state, county, and community efforts.
64 Medical Evaluation for TB Medical history Physical examination Test for TB infection Chest radiograph Bacteriologic examination
65 Medical Evaluation for TB 1. Medical History Symptoms of disease; how long History of TB exposure, infection, or disease Past TB treatment Demographic risk factors for TB Medical conditions that increase risk for TB disease
66 Signs and Symptoms of TB Disease Often of long duration General Fatigue, malaise, weight loss, fever, night sweats Pulmonary Prolonged cough, coughing up blood Extrapulmonary Depends on site
67 Medical Evaluation for TB (cont.) 1. Medical History (cont.) Symptoms of possible extrapulmonary TB: Blood in the urine (TB of the kidney) Headache/confusion (TB meningitis) Back pain (TB of the spine) Hoarseness (TB of the larynx) Loss of appetite, unexplained weight loss Night sweats, fever Fatigue
68 Medical Evaluation for TB (cont.) 2. Physical Examination Provides information about the patient s overall condition Cannot be used to confirm or rule out TB disease
69 Methods for Detecting M. tb Infection in U.S. Mantoux tuberculin skin test (TST) IGRAs: QuantiFERON-TB Gold In-Tube (QFT-GIT), and T-Spot.TB These tests do not exclude LTBI or TB disease Decisions about medical/public health management should include other info/data, and not rely only on TST/IGRA results
70 Medical Evaluation for TB (cont.) 4. Chest Radiograph Chest abnormalities suggest, but do not confirm, TB disease Posterior-anterior view is standard Apical/posterior areas of upper lobe or superior areas of lower lobe often show abnormalities In immunosuppressed (e.g., HIV infected), lesions may have atypical appearance
71 Diagnosis of TB Disease Chest x-ray 95% of HIV(-) cases with upper lobe infiltrates and/or cavities
72 Diagnosis of TB Disease Up to 30% of HIV(+), active TB cases will have no infiltrates or cavities
73 Medical Evaluation for TB (cont.) 5. Bacteriologic Examination of Specimens (cont.) Specimen collection, processing, and review All persons suspected of TB disease should have sputum cultured Collect at least 3 sputum specimens at 8- to 24-hour intervals, at least 1 in the morning Follow infection control precautions during specimen collection Collection methods include coughing, sputum induction, bronchoscopy, gastric aspiration
74 TB Disease Diagnosis Smear Cheap & rapid Only 40-60% positive in cases of active TB The Standard for Diagnosis of TB in most of the world
75 TB Diagnosis Culture Takes 6-8 weeks by conventional Takes 1-3 weeks by liquid media Need ~100 organisms/ml to get 1 colony Sensitivity-Positive in 80% of CDC Verified Cases Specificity- 1-2% False Positive Susceptibility Takes 1-2 weeks after positive culture Molecular Techniques have the ability to give more rapid results Most of the world does not have access to these critical laboratory tests!!!
76 TB Diagnosis Nucleic Acid Amplification Results within eight hours 99% specificity on smear (+) cases Up to 80% sensitivity on three samples $30 to $50 per test Approved by the FDA for smearpositive and negative, untreated cases May have a rule in non-pulmonary samples
77 Major Goals of TB Treatment Cure patient, minimize risk of death/disability, prevent transmission to others Provide safest, most effective therapy in shortest time Prescribe multiple drugs to which the organisms are susceptible Never treat with a single drug or add single drug to failing regimen Ensure adherence and completion of therapy
78 Treatment of Active TB Disease Start with 4 drugs in all patients INH, RIF, PZA and EMB or SM until sensitivities return If pansensitive, D/C EMB or SM After 2 months of therapy, D/C PZA Continue INH & RIF for 4 more months for total of 6 months Must have culture conversion by 2 months 6 month regimen good for HIV(-) and (+) Can use BIW regimen (TIW? RIF Monoresistance in HIV pts after daily for first 2 months) Monitor adherence and toxicity DOT preferred, Combination pills for self administered
79 Directly Observed Therapy (DOT) Health-care worker watches patient swallow each dose DOT is preferred management strategy for all patients Can reduce acquired drug resistance, treatment failure, and relapse Nearly all regimens can be intermittent if given as DOT DOT reduces total number of doses and encounters For drug-resistant TB, use daily regimen and DOT
80 Current Anti-TB Drugs (cont.) Four first-line drugs considered standard treatment: Isoniazid (INH) Rifampin (RIF) Pyrazinamide (PZA) Ethambutol (EMB) Rifabutin and rifapentine also considered first-line drugs in some circumstances Streptomycin (SM) formerly first-line drug, but now less useful owing to increased SM resistance
81 TB Disease Treatment Regimens Four regimens recommended for treatment of drug-susceptible TB, with different options for number of doses and for length of continuation phase Initial phase: standard four drugs (INH, RIF, PZA, EMB) for 2 months (one excludes PZA) Continuation phase: additional 4 months; 7 months for some patients
82 Treatment Completion Defined as ingesting prescribed number of doses within specified time Duration depends on drugs used, isolate s susceptibility, and patient s response to drugs Most patients can be treated with 6-mo. or 9-mo. therapy; 6 mo. is used for most patients
83 Conditions Requiring Additional Considerations Renal insufficiency/end-stage renal disease Some TB drugs are cleared by the kidneys; thus the dosing must be altered with renal disease Rather than decrease dosage size, increase dosing interval Hepatic disease - consider regimens with fewer hepatotoxic agents Extrapulmonary TB - In most cases, treat with same regimens used for pulmonary TB
84 Conditions Requiring Additional Considerations (cont.) Multi-drug resistant TB (MDR TB) Presents high risk for treatment failure, relapse, further acquired resistance, and/or death Clinicians unfamiliar with its treatment should seek expert consultation Always use DOT to ensure adherence
85 All patients Division of Disease Control and Health Protection Baseline Monitoring Patient Recommended Test Measure aminotransferases (i.e., AST, ALT), bilirubin, alkaline phosphatase, and serum creatinine and a platelet count Patients at risk for hepatitis B or C (e.g., injection drug user, born in Asia or, or HIV infected) Patients who are taking EMB Conduct serologic tests Test visual acuity (Snellen chart) and color vision(ishihara) HIV-infected patients Obtain CD4+ lymphocyte count
86 Determinants of Response to Therapy Clinical signs Improved cough usually within two weeks Fever usually within two weeks However can last four to six weeks Weight gain and improved appetite Decreased organisms seen on smear Usually markedly decreased within three to four weeks However can last for months Decreased counts on cultures 90% convert in two months on INH/RIF/PZA
87 Evaluating Response to Treatment (cont.) Monitor for adverse reactions Common adverse reactions include Gastrointestinal problems Hepatitis Rash Fever
88 Likelihood of Infectiousness Probably infectious Positive sputum smears with viable AFB Presence or induction of coughing Not treated or recently started Poor clinical or bacteriologic response to prescription Not infectious Receiving effective therapy and responding Three daily negative sputums
89 Criteria to Be Considered Noninfectious Patients no longer considered infectious if: They have 3 consecutive negative sputum smears (2-3 consecutive negative cultures for MDR), Their symptoms have improved, and They are adhering to an adequate treatment regimen for at least 2 weeks The cultures are negative (despite positive smears)
90 Causes of Inadequate Response to Therapy Non adherence!!!!!!!!!!!!!!!!! DOT Involuntary detention Increased drug resistance/incorrect sensitivities Malabsorption/increased metabolism Inability of drugs to penetrate To effected protect, promote and improve tissues the health of all people in Florida through integrated state, county, and community efforts.
91 Responsibility for TB Control Health departments maintain primary responsibility for TB prevention and control Complexity of TB control requires public health sector to collaborate with others
92 Assure the treatment until cure of every tuberculosis patient!
93 Common Obstacles Adherence Resistance
94 Common Future Vaccine
95 What can you do to combat tuberculosis? Contact local health department to help arrange a plan of therapy for patient-health departments are responsible for the cure of tuberculosis patients Begin four medications on all patients until sensitivity of organisms returns Educate patient about tuberculosis and importance of adherence to medications Consider having patient sign Acknowledgement Form Monitor for effectiveness of therapy, adherence and side effects Consider DOT therapy If DOT therapy fails, consider court ordered DOT Involuntary commitment
96 TB Hotline TB-INFO
TUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More informationCore Curriculum on Tuberculosis: What the Clinician Should Know
Core Curriculum on Tuberculosis: What the Clinician Should Know Sixth Edition 2013 National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination 1 Chapters
More informationTuberculosis Elimination: The Role of the Infection Preventionist
Tuberculosis Elimination: The Role of the Infection Preventionist Preface: What Happens when Health Care Professionals are not familiar with TB? A 15 year old student was diagnosed with highly infectious
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationTuberculosis (TB) Fundamentals for School Nurses
Tuberculosis (TB) Fundamentals for School Nurses June 9, 2015 Kristin Gall, RN, MSN/Pat Infield, RN-TB Program Manager Marsha Carlson, RN, BSN Two Rivers Public Health Department Nebraska Department of
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationTuberculosis 6/7/2018. Objectives. What is Tuberculosis?
Tuberculosis Understanding, Investigating, Eliminating Jeff Maupin, RN Tuberculosis Control Nurse Sedgwick County Division of Health Objectives At the conclusion of this presentation, you will be able
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 7 References Related ACA Standards 4 th Edition Standards for Adult Correctional Institutions 4-4350, 4-4355 These guidelines are based on the recommendations of the American Thoracic Society
More informationRebecca O. Sanchez, BSN., RN., MPH. has the following disclosures to make:
INFECTION CONTROL PRACTICES Rebecca O. Sanchez, RN, BSN, MPH Texas Department of State Health Services Texas Center for Infectious Disease Rebecca O. Sanchez, BSN., RN., MPH. has the following disclosures
More information2017/2018 Annual Volunteer Tuberculosis Notice
Lewis Center for Educational Research Academy for Academic Excellence Norton Science and Language Academy Business Offices 17500 Mana Road Apple Valley, CA 92307 E-mail: hr@lcer.org 760-946-5414 Fax 760-946-9193
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationWhat you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014
What you need to know about diagnosing and treating TB: a preventable, fatal disease Bob Belknap M.D. Denver Public Health November 2014 The Critical First Step Consider TB in the Differential 1. Risks
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationEtiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition
Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis
More informationManaging the Patients Response to TB Treatment
Managing the Patients Response to TB Treatment Barbarah Martinez, RN, BSN September 13, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Barbarah Martinez, RN, BSN has
More informationTuberculosis: A Provider s Guide to
Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency
More informationIntensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite
Intensified TB case finding among PLHIV and vulnerable population Identifying contacts Gunta Kirvelaite Riga East Clinical hospital, Centre for tuberculosis and lung diseases. Head of outpatient department.
More informationChapter 7 Tuberculosis (TB)
Chapter 7 Tuberculosis (TB) TB infection vs. TB disease Information about TB TB skin testing Active TB disease TB risk factors Role of Peel Public Health in TB prevention and control Environmental and
More informationTB Clinical Guidelines: Revision Highlights March 2014
TB Clinical Guidelines: Revision Highlights March 2014 AIR TRAVEL & TB CONTROL With respect to non-ambulance air travel of patients diagnosed with or suspected as having active Mycobacterium tuberculosis,
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationTUBERCULOSIS CONTACT INVESTIGATION
TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE TUBERCULOSIS CONTACT INVESTIGATION LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe the criteria used
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationTB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014
TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014 Catalina Navarro, BSN, RN has the following disclosures to make: No conflict of interests No relevant financial relationships with
More informationTuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director
Tuberculosis What you need to know James Zoretic M.D., M.P.H. Regions 2 and 3 Director What is Tuberculosis? Tuberculosis, (TB) is a communicable disease caused by the Mycobacterium tuberculosis bacillus
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationFLORIDA DEPARTMENT OF JUVENILE JUSTICE DETENTION SERVICES FACILITY MEDICAL POLICIES
FLORIDA DEPARTMENT OF JUVENILE JUSTICE DETENTION SERVICES FACILITY MEDICAL POLICIES Superintendent Signature Designated Health Authority Signature Effective Date: November 1, 2016 Subject: TUBERCULOSIS
More informationLatent TB, TB and the Role of the Health Department
Latent TB, TB and the Role of the Health Department Elaine Darnall, RN, BSN, CIC TB Nurse Consultant Illinois Dept of Public Health March 21, 2018 Elaine Darnall has disclosed that there is no actual or
More informationTB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014
Sharing the Care: Working Together to Meet the Challenge of TB Presented by: Barbara Cole, RN, PHN, MSN Director, Disease Control County of Riverside Department of Public Health Curry International TB
More informationThe Air We Share: Principles and Practices of TB Infection Control
The Air We Share: Principles and Practices of TB Infection Control Session Four of a Four-Part Webinar Series Presented in Partnership with the BC Lung Association January 10, 2014 Facilitators: Nash Dhalla,
More informationContact Investigation
Tuberculosis Ann Raftery, RN, PHN, MSc GHS Learning Objectives Upon completion of this session, participants will be able to: Describe the criteria used and method for determining the infectious period
More informationTB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009
TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages
More informationHEALTHWEST PROCEDURE. No Revised by: Effective: December 1, 1995 Revised: April 19, 2017 Environment of Care Committee
HEALTHWEST PROCEDURE Revised by: Effective: December 1, 1995 Revised: April 19, 2017 Environment of Care Committee Approved by: Subject: Tuberculosis Infection Control Julia Rupp, Executive Director I.
More informationTuberculosis in Chicago 2007
City of Chicago Communicable Disease Information Department of Public Health Richard M. Daley, Mayor May 2008 Terry Mason, MD, FACS, Commissioner www.cityofchicago.org/health/ West Side Center For Disease
More informationTB Contact Investigation Basics
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 TB Contact Investigation Basics Carrie Storrs, RN April 28, 2010 Contact Investigation Carrie Storrs TB Program Illinois Department of Public
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationTB the basics. (Dr) Margaret (DHA) and John (INZ)
TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2
More informationINDEX CASE INFORMATION
Instructions for Completing the MDH Tuberculosis Contact Investigation Report Form Please provide as much information as possible. Each field represents information that is important to the contact investigation.
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Childhood Tuberculosis Kim Smith, MD, MPH April 6, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationAt the end of this session, participants will be able to:
Advanced Concepts in Pediatric Tuberculosis: Infection Control, Source Case and Contact Investigation Ana M. Alvarez, M.D. Associate Professor Division of Pediatric Infectious Diseases and Immunology University
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationReplaces: 02/11/16. Formulated: 7/95 EMPLOYEE TB TESTING
Effective : 02/09/17 Page 1 of 4 PURPOSE: To describe the process where by employees may obtain routine TB skin testing by facility medical staff. POLICY: Employees of the Texas Department of Criminal
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Contact Investigation in the Correctional Setting Jessica Quintero, BAAS March 24, 2011 Jessica Quintero, BAAS has the following disclosures to make: No
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 Pediatric TB Kim Smith, MD, MPH July 19, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationTuberculosis Procedure ICPr016. Table of Contents
Tuberculosis Procedure ICPr016 Table of Contents Tuberculosis Procedure ICPr016... 1 What is Tuberculosis?... 2 Any required definitions/explanations... 2 NHFT... 2 Tuberculosis (TB)... 3 Latent TB...
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 12 PURPOSE To provide guidelines for the prevention and the treatment of tuberculosis (TB) in the N.C. Department of Correction. POLICY The N. C. Department of Correction will abide by this Tuberculosis
More informationTB Contact Investigation
Ann Raftery, RN, PHN, MS Curry International TB Center Overview Contact investigation as a core TB control and elimination activity Components of TB Contact Investigation TB Control Priority Strategies.
More informationTuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats
Tuberculosis Facts Below are frequently asked questions about TB, and their answers. If you have additional questions you may contact the City of Ennis Department of Health Services at 972-875-1234 or
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More information"GUARDING AGAINST TUBERCULOSIS IN INSTITUTIONAL FACILITIES"
MAJOR PROGRAM POINTS "GUARDING AGAINST TUBERCULOSIS IN INSTITUTIONAL FACILITIES" Training For THE CDC "TUBERCULOSIS PREVENTION GUIDELINES" "Quality Safety and Health Products, for Today...and Tomorrow"
More informationMODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE SIX Global TB Institutions and Policy Framework Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be Covered Global TB policy and coordinating structures The Stop TB Strategy TB/HIV collaborative
More informationIntroduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015
Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Initiation Phase Part 1 Ginny Dowell, RN, BSN February 4, 2015 Ginny Dowell RN, BSN has the following disclosures to make:
More informationTB Nurse Assessment. Ginny Dowell, RN, BSN October 21, 2015
TB Nurse Assessment Ginny Dowell, RN, BSN October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19-22, 2015 Wichita, KS EXCELLENCE EXPERTISE INNOVATION Ginny Dowell,
More informationErrors in Dx and Rx of TB
Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a
More informationTuberculosis & Refugees in Philadelphia
Tuberculosis & Refugees in Philadelphia Philadelphia TB Control Program Daniel P. Dohony, MPH Philadelphia TB Control Program Health Information Portal Website: hip.phila.gov Contains Information On» Disease
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More informationYakima Health District BULLETIN
Yakima Health District BULLETIN Summary Volume 13, Issue 1 February, 2014 Tuberculosis in Yakima County The rate of active tuberculosis (TB) in Yakima County has declined by about two-thirds over the past
More informationChapter 4 Diagnosis of Tuberculosis Disease
Chapter 4 Diagnosis of Tuberculosis Disease Table of Contents Chapter Objectives.... 75 Introduction.... 77 Medical Evaluation.......................................................... 78 Chapter Summary...
More informationTUBERCULOSIS TODAY WORLD-WIDE, UNITED STATES, TEXAS J O R D A N C O U L S O N, R. N. S N S C O O R D I N A T O R, P H E P / H S R 1
TUBERCULOSIS TODAY WORLD-WIDE, UNITED STATES, TEXAS J O R D A N C O U L S O N, R. N. S N S C O O R D I N A T O R, P H E P / H S R 1 WHAT IS TB? TB is a disease caused by a bacterium called Mycobacterium
More information2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
More informationStop TB Poster (laminated copies are available from TB Control: )
Tuberculosis Prevention and Control Recommendations For Homeless Shelters in Maine Tool Kit What Your Shelter Can Do to Prevent TB Assessing Your Shelter Guests Risk for TB Cough Alert Policy Think TB
More information#114 - Tuberculosis Update [1]
Published on Excellence In Learning (https://excellenceinlearning.net) Home > #114 - Tuberculosis Update #114 - Tuberculosis Update [1] Please login [2] or register [3] to take this course. $8.00 Course
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More informationTB and Respiratory Protection
Slide 1 TB and Respiratory Protection Tuberculosis (TB) is a disease present throughout the United States. Lehigh Valley Health Network is concerned about your health and needs your help to prevent the
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationQuestions and Answers About
Questions and Answers About TB 2005 DEPARTMENT OF HEALTH AND HUMAN SERVICES TB Elimination Questions and Answers About TB 2005 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationThese recommendations will remain in effect until the national shortage of PPD solution has abated.
Maryland Recommendations Regarding the National Shortage of Purified Protein Derivative (PPD) Solution; Attachment to Health Officer Memorandum National Shortages of Tubersol and Aplisol for TB Skin Testing;
More informationTuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)
Tuberculosis Reporting, Waco-McLennan County Public Health District TB Control WMCPHD (254)-750-5496 Local health care providers, including physicians offices, labs and hospitals, are required by law to
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Transmission and Pathogenesis of Tube rc ulos is U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for HIV/AIDS,
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationChapter 22. Pulmonary Infections
Chapter 22 Pulmonary Infections Objectives State the incidence of pneumonia in the United States and its economic impact. Discuss the current classification scheme for pneumonia and be able to define hospital-acquired
More informationCommunity pharmacy-based tuberculosis skin testing
Community pharmacy-based tuberculosis skin testing Shanna K. O Connor, PharmD ISU KDHS Spring CE Seminar 2018 In support of improving patient care, Idaho State University Kasiska Division of Health Sciences
More informationArizona Annual Tuberculosis Surveillance Report
Arizona Annual Tuberculosis Surveillance Report 2014 Table of Contents I. Executive Summary 1 II. Case Rates 3 III. Cases and Case Rates by Race and Ethnicity 4 IV. Cases by Gender 4 V. Cases and Case
More information"GUARDING AGAINST TUBERCULOSIS IN HEALTHCARE FACILITIES"
MAJOR PROGRAM POINTS "GUARDING AGAINST TUBERCULOSIS IN HEALTHCARE FACILITIES" Training For THE CDC "TUBERCULOSIS PREVENTION GUIDELINES" "Quality Safety and Health Products, for Today...and Tomorrow" Outline
More informationTB Program Management San Antonio, Texas November 5-7, 2008
TB Program Management San Antonio, Texas November 5-7, 2008 Infection Control Lynelle Phillips, RN, MPH November 7, 2008 Infection Control Lynelle Phillips, RN MPH Nurse Consultant Heartland National TB
More informationTB CONTROL IN HEALTHCARE FACILITIES: A PRACTICAL GUIDE FOR PREVENTION
TB CONTROL IN HEALTHCARE FACILITIES: A PRACTICAL GUIDE FOR PREVENTION HOW TB IS SPREAD GENERATION OF TB DROPLET NUCLEI One cough produces 500 droplets Average TB patient generates 75,000 droplets/day (before
More informationPreventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program
Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program Topics of Discussion TB Overview Epidemiology of TB in Oregon Annual Facility
More information11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction
SECOND EDITION 2009 Madhukar Pai McGill University Introduction 1 Purpose of ISTC ISTC Version 2: Key Points 21 Standards Differ from existing guidelines: standards present what should be done, whereas,
More informationTB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks
1 TB facts & figures Microbiology of TB Transmission of TB Infection control in health care settings Special cases Resistant TB Masks 2 Page 1 4 NHS Lothian Infection Prevention and Control Study Day On
More informationCHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!
More informationTB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)
TB IN EMERGENCIES Department of Epidemic and Pandemic Alert and Response (EPR) Health Security and Environment Cluster (HSE) (Acknowledgements WHO Stop TB Programme WHO/STB) 1 Why TB? >33% of the global
More informationScott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer
Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of
More informationTB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012
TB Nurse Case Management San Antonio, Texas March 7 9, 2012 Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012 Kim Connelly Smith, MD, MPH has the following disclosures to make: No conflict of interests
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More information